
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis
On June 10, 2025, Arcutis Biotherapeutics announced that the first infant was enrolled in the INTEGUMENT-INFANT study, a phase 2 clinical trial evaluating investigational roflumilast cream 0.05% for atopic dermatitis (AD) in children aged 3 months to under …